AACR 2013
American Association for Cancer Research Annual Meeting
Interviews and expert commentary from AACR 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.
BRCA-deficient cancers respond to combination of two experimental drugs
WASHINGTON DC—Doctors taking the unusual step of combining two experimental drugs to treat cancers in patients who have mutated BRCA — the gene conferring susceptibility to breast, ovarian and some ot
Treatment “holidays” to overcome resistance in advanced melanoma?
WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presente
Gene expression and molecular pathways guide head and neck cancer therapies
WASHINGTON DC—Gene expression and molecular pathways in head and neck cancer have been identified with reference to The Cancer Genome Atlas in research presented at the American Association for Cancer
Treating HER 2 positive metastatic breast cancer without chemotherapy?
WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to
Two-step immunotherapy brings promise in advanced ovarian cancer
WASHINGTON DC—A new type of immunotherapy has helped patients with advanced ovarian cancer who had no other therapeutic options. In a study reported to the 2013 conference of the American Association